Multicenter Prospective Investigation on Efficacy and Safety of Carperitide as a First-Line Drug for Acute Heart Failure Syndrome With Preserved Blood Pressure : COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated Heart
スポンサーリンク
概要
- 論文の詳細を見る
Background Recently, vasodilators have been increasingly being recognized as useful for the treatment of acute heart failure syndromes (AHFS). Although carperitide (α-human atrial natriuretic peptide) has vasodilatory, diuretic and organ-protective effects, its efficacy and safety for the first-line drug treatment of AHFS have not been reported. Methods and Results A prospective observational study was performed in AHFS patients with preserved systolic blood pressure (SBP ≥120mmHg), pulmonary congestion and dyspnea who were receiving carperitide monotherapy. The analysis was conducted in 1,832 patients (male: 52.7%; mean age: 75.1±12.7 years). The initial SBP was 151.1±25.7mmHg; 62.0% were diagnosed as having acutely decompensated chronic heart failure and 78.8% were assessed as functional class III-IV according to New York Heart Association classification. Carperitide was administered at an initial dosage of 0.025-0.05μg.kg^<-1>・min<-1> in 50.4% of patients. In 1,524 patients (83.2%), carperitide monotherapy restored the acute phase and improved the degree of dyspnea as assessed using the modified Borg scale. The incidence of adverse drug reactions was 4.64%; the most frequently reported adverse reaction was hypotension (3.55%). Conclusion In the present study, following carperitide monotherapy, 83.2% of AHFS patients recovered from the acute phase. Based on these findings, carperitide seems useful for the first-line drug treatment of AHFS in patients with pulmonary congestion and preserved blood pressure.
- 2008-10-20
著者
-
Mori Yoshihiro
Post-marketing Study Department Quality And Safety Management Division Daiichi-sankyo Company Limite
-
Kawai Masanori
Pharmacovigilance And Clinical Safety Department Asubio Pharma Company Limited
-
Nomura Fumihiro
Marketing Department, Marketing and Sales Division, Daiichi-Sankyo Company Limited
-
Kurobe Nobushige
Post-Marketing Study Department, Quality and Safety Management Division, Daiichi-Sankyo Company Limi
-
Hikita Atsushi
Pharmacovigilance and Clinical Safety Department, Asubio Pharma Company Limited
-
Suwa Mitsuru
Pharmacovigilance and Clinical Safety Department, Asubio Pharma Company Limited
-
Okutani Yukihiro
Product Lifecycle Management Department, Daiichi-Sankyo Company Limited
-
Suwa Mitsuru
Pharmacovigilance And Clinical Safety Department Asubio Pharma Company Limited
-
Hikita Atsushi
Pharmacovigilance And Clinical Safety Department Asubio Pharma Company Limited
-
Nomura Fumihiro
Marketing Department Marketing And Sales Division Daiichi-sankyo Company Limited
-
Kurobe Nobushige
Post-marketing Study Department Quality And Safety Management Division Daiichi-sankyo Company Limite
-
Okutani Yukihiro
Product Lifecycle Management Department Daiichi-sankyo Company Limited